Role of immunohistochemistry in diagnosing tumors of cutaneous appendages

American Journal of Dermatopathology

Volumn 33, Issue 8, 2011, Pages 765-774

  Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apocrine neoplasm; Eccrine neoplasm; Follicular neoplasm; Immunohistochemistry

Indexed keywords

ADIPOPHILIN; ANDROGEN RECEPTOR; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; CD23 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 10; CYTOKERATIN 15; CYTOKERATIN 17; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; MISMATCH REPAIR PROTEIN PMS2; NESTIN; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P63; PROTEIN P75;

ARTICLE; BASAL CELL CARCINOMA; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HIDRADENOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MERKEL CELL; MICROCYSTIC ADNEXAL CARCINOMA; MUIR TORRE SYNDROME; PRIORITY JOURNAL; SEBACEOUS CARCINOMA; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; SWEAT GLAND CARCINOMA; SWEAT GLAND TUMOR; TRICHOBLASTOMA; TRICHOEPITHELIOMA; TUMOR BIOPSY; TUMOR DIAGNOSIS;

BIOPSY; CARCINOMA, SKIN APPENDAGE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, ADNEXAL AND SKIN APPENDAGE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 82455168121     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31820a4837     Document Type: Article

References (91)

1. Jimenez FJ, Burchette JL Jr, Grichnik JM, et al. BerEP4 immunoreactivity in normal skin and cutaneous neoplasms. Mod Pathol. 1995;8:854-858.
2. Beer TW, Shepherd P, Theaker JM. Ber-EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37:218-223.
3. Fan YS, Carr RA, Sanders DS, et al. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology. 2007;51:80-86. (Pubitemid 46976369)
4. Swanson PE, Fitzpatrick MM, Ritter JH, et al. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol. 1998;25:153-159. (Pubitemid 28130161)
5. Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34:782-787. (Pubitemid 47459695)
6. Tellechea O, Reis JP, Domigues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous cell carcinoma of the skin. Am J Dermatopathol. 1993;15:452-455. (Pubitemid 23303048)
7. Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: An immunohistochemical reappraisal. Mod Pathol. 2008;21:178-185. (Pubitemid 351172169)
8. Ishida M, Kushima R, Okabe H. Aberrant expression of class III betatubulin in basal cell carcinoma of the skin. Oncol Rep. 2009;22:733-737.
9. Heyderman E, Graham RM, Chapman DV, et al. Epithelial markers in primary skin cancer: An immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology. 1984;8:423-434. (Pubitemid 14107614)
10. Tatemoto Y, Saka M, Tanimura T, et al. Immunohistochemical observations on binding of monoclonal antibody to epithelial membrane antigen in epithelial tumors of the oral cavity and skin. Oral Surg Oral Med Oral Pathol. 1987;64:721-726. (Pubitemid 18029363)
11. Yada K, Kashima K, Daa T, et al. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004;26:463-471. (Pubitemid 40082510)
12. Pham TT, Selim MA, Burchette JL Jr, et al. CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol. 2006;33: 123-128.
13. Wagnoner J, Keehn C, Morgan MB. CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol. 2007;29:555-558. (Pubitemid 350158867)
14. Yu L, Galan A, McNiff JM. Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol. 2009;36:1074-1076.
15. Tope WD, Nowfar-Rad M, Kist DA. Ber-EP4-positive phenotype differentiates actinic keratosis from superficial basal cell carcinoma. Dermatol Surg. 2000;26:415-418. (Pubitemid 30305317)
16. Katona TM, Perkins SM, Billings SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol. 2008;35:174-179.
17. Costache M, Bresch M, Boer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: A critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology. 2008;52:865-876. (Pubitemid 351724908)
18. Izikson L, Bhan A, Zembowicz A. Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol. 2005;27:91-95. (Pubitemid 40471092)
19. Abesamis-Cubillan E, El-Shabrawi-Caelen L, LeBoit PE. Merkel cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22:311-315. (Pubitemid 30618612)
20. Hartschuh W, Schulz T. Merkel cells are integral constituents of desmoplastic trichoepithelioma: An immunohistochemical and electron microscopic study. J Cutan Pathol. 1995;22:413-421.
21. Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: A sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999;21:426-431. (Pubitemid 29491268)
22. Collina G, Eusebi V, Capella C, et al. Merkel cell differentiation in trichoblastoma. Virchows Arch. 1988;433:291-296.
23. Schulz T, Hartschuh W. Merkel cells are absent in basal cell carcinomas but frequently found in trichoblastomas. An immunohistochemical study. J Cutan Pathol. 1997;24:14-24. (Pubitemid 27060072)
24. Kirchmann TT, Prieto VG, Smoller BR. CD34 staining pattern distinguishes basal cell carcinoma from trichoepithelioma. Arch Dermatol. 1994;130:589-592. (Pubitemid 24150937)
25. Ishida M, Kushima R, Okabe H. Immunohistochemical demonstration of D2-40 in basal cell carcinomas of the skin. J Cutan Pathol. 2008;35: 926-930.
26. Kurzen H, Esposito L, Langbein L, et al. Cytokeratins as markers of follicular differentiation: An immunohistochemical study of trichoblastoma and basal cell carcinoma. Am J Dermatopathol. 2001;23:501-509. (Pubitemid 33086477)
27. Krahl D, Sellheyer K. p75 Neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: Insights into the histogenesis of adnexal tumours based on embryology and hair follicle biology. Br J Dermatol. 2010;163:138-145.
28. Lyle S, Christofidou-Solomidou M, Liu Y, et al. The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human follicle stem cells. J Cell Sci. 1998;111:3179-3188. (Pubitemid 28532428)
29. Jih DM, Lyle S, Elenitsas R, et al. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J Cutan Pathol. 1999;26:113-118. (Pubitemid 29161162)
30. Carvalho J, Fullen D, Lowe L, et al. The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol. 2007;34:693-698. (Pubitemid 47256246)
31. Bogner PN, Su LD, Fullen DR. Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J Cutan Pathol. 2005;32:50-54. (Pubitemid 40174106)
32. Smith KJ, Williams J, Corbett D, et al. Microcystic adnexal carcinoma: An immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25:464-471. (Pubitemid 32240885)
33. Wick MR, Cooper PH, Swanson PE, et al. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol. 1990;126:189-194.
34. Vidal CI, Goldberg M, Burstein DE, et al. P63 immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol. 2010;32:257-261.
35. Lozano Orella JA, Valcayo Penalba A, San Juan CC, et al. Eccrine porocarcinoma: Report of nine cases. Dermatol Surg. 1997;23:925-928. (Pubitemid 27476112)
36. Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: A clinicopathologic study of 35 cases. Arch Dermatol. 1983;119:104-114. (Pubitemid 13189205)
37. Shaw M, McKee PH, Lowe D, et al. Malignant eccrine poroma: A study of twenty-seven cases. Br J Dermatol. 1982;107:675-680. (Pubitemid 13238866)
38. Shiohara J, Koga H, Uhara H, et al. Eccrine porocarcinoma: Clinical and pathological studies of 12 cases. J Dermatol. 2007;34:516-522. (Pubitemid 47228526)
39. Robson A, Green J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): A clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710-720. (Pubitemid 32496860)
40. Goh SG, Dayrit JF, Calonje E. Sarcomatoid eccrine porocarcinoma: Report of two cases and a review of the literature. J Cutan Pathol. 2007; 34:55-60. (Pubitemid 46066528)
41. Pulitzer M, Desman G, Busam KJ. CK7 expression in primary cutaneous squamous cell carcinoma. J Cutan Pathol. 2010;37:966-972.
42. Ansai S, Koseki S, Hozumi Y, et al. An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Am J Dermatopathol. 1995;17: 249-255.
43. Mahalingam M, Nguyen LP, Richards JE, et al. The diagnostic utility of immunohistochemistry in distinguishing primary adnexal carcinomas from metastatic adenocarcinoma to skin: An immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol. 2010;23:713-719.
44. Wollina U, Castelli E, Ralke D. Immunohistochemistry of eccrine poroma and porocarcinoma-more than acrosyringeal tumors? Recent Results Cancer Res. 1995;139:303-316.
45. Wong TY, Suster S, Nogita T, et al. Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients. Cancer. 1994;15: 1631-1643. (Pubitemid 24085263)
46. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: A histological and immunohistochemical study. J Cutan Pathol. 2006;33:726-730. (Pubitemid 44704324)
47. Berg J, McDivitt RW. Pathology of sweat gland carcinoma. Pathol Ann. 1968;3:123-144.
48. Keasbey LE, Hadley GG. Clear-cell hidradenoma: Report of three cases with widespread metastases. Cancer. 1954;7:934-952.
49. Hernandez-Parez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma. A 10-year review. J Am Acad Dermatol. 1985;12: 15-20. (Pubitemid 15192647)
50. Headington JT, Niederhuber JE, Beals TF. Malignant clear cell acrospiroma. Cancer. 1978;41:641-647. (Pubitemid 8289277)
51. Santa Cruz DJ. Sweat gland carcinomas: A comprehensive review. Semin Diagn Pathol. 1987;4:38-74.
52. Kersting DW. Clear cell hidradenoma and hidradenocarcinoma. Arch Dermatol. 1963;87:323-333.
53. Chung CK, Hefferman AH. Clear cell hidradenoma with metastasis: Case report with a review of the literature. Plast Reconstr Surg. 1971;48: 177-179.
54. Mambo NC. The significance of atypical nuclear changes in benign eccrine acrospiromas: A clinical and pathological study of 18 cases. J Cutan Pathol. 1984;11:35-44. (Pubitemid 14184278)
55. Nazarian RM, Kapur P, Rakheja D, et al. Atypical and malignant hidradenomas: A histologic and immunohistochemical study. Mod Pathol. 2009;22:600-610.
56. Ostler DA, Prieto VG, Reed JA, et al. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: An immunohistochemical study of 117 cases. Mod Pathol. 2010;23:567-573.
57. Sramek B, Lisle A, Loy T. Immunohistochemistry in ocular carcinomas. J Cutan Pathol. 2008;35:641-646. (Pubitemid 351813393)
58. Yang HM, Cabral E, Dadras SS, et al. Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol. 2008;30:549-554.
59. Shields JA, Demirici H, Marr BOP, et al. Sebaceous carcinoma of the ocular region: A review. Surv Ophthalmol. 2005;50:103-122. (Pubitemid 40340946)
60. Shields JA, Demirici H, Marr BOP, et al. Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology. 2004;111: 2151-2157. (Pubitemid 39575582)
61. Yeatts RP, Waller RR. Sebaceous carcinoma of the eyelid: Pitfalls in diagnosis. Ophthal Plast Reconstr Surg. 1985;1:35-42. (Pubitemid 16079172)
62. Zurcher M, Hintschich CR, Garner A, et al. Sebaceous carcinoma of the eyelid: A clinicopathological study. Br J Ophthalmol. 1998;82:1049-1055. (Pubitemid 28451278)
63. Muthusamy K, Halbert G, Roberts F. Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol. 2006;59:1166-1170. (Pubitemid 44787136)
64. Ansai S, Hashimoto H, Aoki T, et al. A histochemical and immunohistochemical study of extra-ocular sebaceous carcinoma. Histopathology. 1993;22:127-133. (Pubitemid 23067132)
65. Ansai S, Katagata Y, Yoshikawa K, et al. An immunohistochemical study of sebaceous carcinoma with anti-keratin monoclonal antibodies: Comparison with other skin cancers. J Dermatol. 1994;21:553.
66. Johnson JS, Lee JA, Cotton DW, et al. Dimorphic immunohistochemical staining in ocular sebaceous neoplasms: A useful diagnostic aid. Eye. 1999;13:104-108. (Pubitemid 29121607)
67. Sinard JH. Immunohistochemical distinction of ocular sebaceous carcinoma from basal cell and squamous cell carcinoma. Arch Ophthalmol. 1999;117:775-783.
68. Izumi M, Mukai K, Nagai T, et al. Sebaceous carcinoma of the eyelids: Thirty cases from Japan. Pathol Int. 2008;58:483-488. (Pubitemid 351952023)
69. Plaza JA, Ortega PF, Stockman DL, et al. Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: A clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol. 2010;37: 403-410.
70. Shikata N, Kurokawa I, Andachi H, et al. Expression of androgen receptors in skin appendage tumors: An immunohistochemical study. J Cutan Pathol. 1995;22:149-153.
71. South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100: 277-281. (Pubitemid 351480531)
72. Chhibber V, Dresser K, Mahalingam M. MSH-6: Extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164. (Pubitemid 351172167)
73. Popnikolov NK, Gatalica Z, Colombe-Grimmer MI, et al. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol. 2003:30:178-184. (Pubitemid 36428426)
74. Orta L, Klimstra DS, Qin J, et al. Towards identification of hereditary DNA mismatch repair deficiency: Sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol. 2009:33:934-944.
75. Abbott JJ, Hernandez-Rios P, Amirkhan RH, et al. Cystic sebaceous neoplasm in Muir-Torre syndrome. Arch Pathol Lab Med. 2003;127: 614-617. (Pubitemid 36534950)
76. Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32:936-942.
77. Wallace ML, Longacre TA, Smoller BR. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol. 1995;8:897-901. (Pubitemid 26025965)
78. Sariya D, Ruth K, Adams-McDonell R, et al. Clinicopathologic correlation of cutaneous metastases: Experience from a cancer center. Arch Dermatol. 2007;143:613-620. (Pubitemid 46799848)
79. Qureshi HS, Ormsby AH, Lee MW, et al. The diagnostic utility of p63, CK5/6, CK7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. J Cutan Pathol. 2004;31:145-152. (Pubitemid 38130424)
80. Ivan D, Diwan AH, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18:137-142. (Pubitemid 40128106)
81. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol. 2007;31:304-310. (Pubitemid 46175033)
82. Plump SJ, Argenyi ZB, Stone MS, et al. Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma. Am J Dermatopathol. 2004;26:447-451. (Pubitemid 40082507)
83. Kanitakis J, Chouvet B. Expression of p63 in cutaneous metastases. Am J Clin Pathol. 2007;128:753-758. (Pubitemid 350133985)
84. Levy G, Finkelstein A, McNiff JM. Immunohistochemical techniques to compare primary vs. metastatic mucinous carcinoma of the skin. J Cutan Pathol. 2010;37:411-415.
85. Ivan D, Hafeez DA, Prieto VG, et al. Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol. 2007:34:474-480. (Pubitemid 46791198)
86. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 650 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989:20:281-287. (Pubitemid 19081966)
87. Wick M, Ockner DM, Mills SE, et al. Homologous carcinomas of the breasts, skin and salivary glands: A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma and salivary duct carcinoma. Am J Clin Pathol. 1998;109:75-84. (Pubitemid 28023814)
88. Chu P, Wu D, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol. 2000;13: 962-972.
89. Langel DJ, Yeatts RP, White WL. Primary signet ring cell carcinoma of the eyelid: Report of a case demonstrating further analogy to lobular carcinoma of the breast with a literature review. Am J Dermatopathol. 2001;23:444-449. (Pubitemid 32938915)
90. Hood CI, Font RL, Zimmerman LE. Metastatic mammary carcinoma in the eyelid with histiocytoid appearance. Cancer. 1973;31:793-800.
91. Kiyohara T, Kumakiri M, Kouraba S, et al. Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 positivity. J Am Acad Dermatol. 2006;54:532-536. (Pubitemid 43243464)